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Introduction 
There is little doubt that tumor necrosis fac- 
tor received center stage attention in biomed- 
ical research circles during the 1980s. Interest 
in this cytokine was not restricted to molecu- 
lar biologists in biotechnology firms, but in- 
cluded cell and molecular biologists and 
whole animal physiologists in disciplines as 
diverse as pharmacology, pathology and 
surgery. As scientific studies now enter the 
1990s, interest in this cytokine has yet to 
peak. The pleomorphic effects of TNF in 
both physiologic and immunologic systems 
are the driving forces behind much of the 
investigative excitement that surrounds this 
cytokine. 
For example, while low levels of TNF may 
be involved in the maintenance of physiologic 
homeostasis, elevated levels of TNF, associ- 
ated with normal inflammation, may repre- 
sent nothing more than an increase in 
homeostatic levels. Intense inflammatory pro- 
cesses with subsequent tissue injury also have 
been associated with this cytokine, although 
the production of TNF in these cases appear 
to be both exaggerated and protracted. In the 
latter scenario, life threatening consequences 
may ensue. Thus, this cytokine has been 
shown to possess numerous functional activi- 
ties at the systemic, tissue, or cellular levels 
depending upon the concentration of TNF 
being synthesized. 
Interestingly, the widespread activity of 
TNF appears to be due to the equally wide- 
spread expression of TNF receptors on a 
variety of cells [1, 2]. Tumor necrosis factor 
can interact with a variety of immune/inflam- 
matory cells, including lymphocytes [3,4], 
mononuclear phagocytes [5,6], and neu- 
trophils [7, 8], as well as non-immune cells, 
such as fibroblasts [9, 10], endothelial cells 
[11, 12], and epithelial cells [ 13]. Considering 
the wide array of non-transformed cells that 
are suspectible to non-lytic stimulation by 
TNF, it is not surprising that active research 
remains directed at understanding the func- 
tion of this cytokine. 
One avenue of intense investigation is di- 
rected as assessing the production of TNF by 
stimulatory agents that have physiologic sig- 
nificance and connecting this synthesis with in 
vivo pathophysiologic events. A second area 
of interest concerns the regulation of TNF at 
the cellular and molecular levels. Studies ex- 
amining the regulation of TNF will prove to 
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be especially important, as it now appears 
that TNF is a proximal mediator and 
plays a central role in cytokine network- 
ing. A phenomenon whereby one cytokine, 
such as TNF, can induce the expression 
of an additional cytokine and establish a 
cascade effect. Thus, the modulation of 
this early response polypeptide may have a 
great impact on the synthesis of more distal 
mediators. 
In the following manuscript concepts and 
data are presented that explore the involve- 
ment of TNF in the diverse pathophysiologic 
events of ischemia/reperfusion injury and the 
rejection of a transplanted organ. Although 
the importance of TNF as a proximal medi- 
ator is apparent during ischemia/reperfusion 
injury, this polypeptide is nonetheless impor- 
tant in chronic delayed type hypersensitivity 
processes that are operative during trans- 
plant rejection. The importance of TNF in 
both acute and chronic immune/inflamma- 
tory mechanism underscores the importance 
of studying regulatory circuits that control 
the production of this mediator. A number 
of studies have shown that macrophage- 
derived TNF can be regulated at either the 
transcriptional or posttranscriptional levels 
by a variety of compounds, including 
steroids, lipids and other polypeptides. The 
efficacy of these endogenous regulators 
on the production of TNF (in the context 
of acute and chronic disease states) will 
prove to be an exciting and worthy area of 
research. 
The in vivo significance of TNF 
To fully appreciate the in vivo significance of 
TNF one must examine the cytokine from a 
historic perspective. For some of the earliest 
cytolytic studies on TNF pre-dates modern 
investigations by a century. The experimental 
data generated by Dr. Coley and others 
demonstrated that specific bacterial products, 
including lipopolysaccharide (LPS), was of 
potential therapeutic value in the treatment of 
inoperable head and neck sarcomas. These 
insightful studies essentially showed that hu- 
mans treated with LPS could generate a factor 
that would induce the necrosis of specific solid 
tumors. This general research theme was re- 
assessed years later when Carwell et al. [14] 
discovered a tumor-lytic polypeptide in the 
blood of BCG immunized mice challenged 
with endotoxin. Both of these "early" studies 
were crucial in establishing the observation 
that the administration of LPS to an intact 
animal could contribute to cytotoxicity. 
Subsequent studies soon capitalized on 
these observations and demonstrated that 
many of the physiologic effects of LPS are 
mediated via the synthesis and release of 
soluble TNF [15-18]. Support for the hypo- 
thesis that TNF was one of the major 
polypeptide mediators involved in the patho- 
genesis of bacterial sepsis soon gained mo- 
mentum. In a number of in vivo models, either 
LPS or gram negative bacteria could induce a 
shock-like state characterized by hypotension, 
malaise, fever, and respiratory failure 
[15, 17, 19, 20]. Histologically these experi- 
mental animals presented with renal tubular 
necrosis, ischemic changes in the small bowel, 
and pulmonary edema. Compelling data that 
supported the role of TNF in the above 
alterations were presented in passive immu- 
nization studies using antibodies directed 
against TNF [17, 21]. In addition, the direct 
infusion of TNF into experimental animals 
was found to mimic many of the effects of 
LPS. The administration of TNF has been 
reported to induce a metabolic acidosis [22], 
decrease the partial pressure of carbon dioxide 
[22,23], increase the stress hormones 
epinephrine, norepinephrine and glucagon 
[23] and alter glucose metabolism [23]. 
The clinical importance of TNF 
Clinical studies have also established a 
provocative link between systemic TNF levets 
and septic states. In the seminal studies by 
Waage et al. [24, 25] TNF was found in the 
sera of patients with meningococcal sep- 
ticemia and, the levels of TNF correlated 
with morbidity and mortality [25]. Unfortu- 
nately the treatment of septic shock is pri- 
marily supportive, as totally efficacious 
therapy remains an enigma. Past therapeutic 
approaches advocated the use of high dose 
steroids for the treatment of septic shock 
[26], but prospective studies demonstrated 
this protocol had no effect on the final out- 
come of the syndrome [27]. Mechanistic stud- 
ies, as to why steroids would not be useful in 
treating disease states associated with LPS- 
dependent increases in TNF, demonstrated 
that TNF is an extremely proximal mediator 
and therapy can not be delivered in time to 
negate its production [28]. The induction of 
TNF gene transcription and protein transla- 
tion is now known to be a rapid event after 
LPS challenge [28, 29]. Steroid treatment can 
only control TNF gene expression if given 
prior to LPS challenge or simultaneously 
with the LPS. Thus, the clinical usefulness of 
steroid therapy in controlling LPS-dependent 
septic states appear to be of little value. 
TNF in ischemia/repeffusion injury 
Although TNF does appear to be involved in 
the pathologic alternations of sepsis, this dis- 
ease state is not the only clinically important 
process in which TNF may have a leading 
role. Elevated levels of TNF appear to be 
involved in the inflammatory processes asso- 
ciated with other specific disease states, in- 
cluding diseases of parasitic origin [30], 
autoimmune joint disease [31], allograft rejec- 
tion [32] and viral disease [33]. Increased 
levels of TNF have also been found in pa- 
tients with HIV infection and in many cases 
the concentration of TNF correlates with the 
clinical course of the disease [33]. In addition, 
recent studies from our laboratory have 
demonstrated that this interesting cytokine is 
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involved in the adverse changes that occur 
during ischemia/reperfusion [34]. Using an 
established model of lobar ischemia/reperfu- 
sion, rather than total hepatic ischemia, an 
ischemic insult to the liver was induced with- 
out inducing mesenteric venous hypertension. 
A microaneurysm clip was used in these stud- 
ies to stop both portal venous and hepatic 
arterial blood flow to the 3 cephalad lobes of 
the liver, while the 3 caudal lobes retained 
normal portal and venous flow. This aspect 
of the rat model is important, as intestinal 
venous congestion was prevented which 
negated bacterial translocation from a poten- 
tially ischemic small bowel. As shown in 
Table 1, the levels of bioactive TNF found in 
the sera correlated with the length of is- 
chemia. In these studies a catheter was posi- 
tioned in the supra-hepatic vena cava in 
order to obtain immediate post-hepatic blood 
samples. Ninety minutes of ischemia proved 
to be of significant time to induce the synthe- 
sis of TNF. In subsequent kinetic analyses, 
TNF was monitored in the sera at specific 
time intervals post reperfusion. The peak in 
TNF levels were found to be variable as they 
reached a zenith by 3 hours post reperfusion. 
The peak concentration of TNF ranged be- 
tween 9-141 pg/ml of rat serum. Pathology 
induced by the hepatic ischemia/reperfusion 
was identified as a neutrophilic sequestra- 
tion with edematous changes in the lungs 
(Table 2). The histologic alterations in the 
lungs may not be too surprising considering 
that the next vascular bed past the liver is in 
Table 1. Kinetics of mean plasma TNF production following 
various periods of ischemia and reperfusion. 
Tumor necrosis factor (pg/ml) 
lschemia 
time Reperfusion time in minutes 
(minutes) 15 30 45 60 90 120 180 210 
45 2.0 5 . . . .  
60 . . . . . . .  10 
75 5.0 2.0 2.0 2.0 18 20 42 
90 - 2,0 5 12 85 20 - 
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Table Z Pathologic parameters assessing tung injury following 
90 minutes partial hepatic ischemia and various reperfusion 
times. 
Reperfusion time # RBC/Alveolus Permeability 
hours index a 
0 0.1 
1 
3 2 0.3 
6 4 0,4 
9 0.6 
12 24 0.55 
~Permeabitity index was determined by monitoring the influx 
of 1251-labelled serum albumin into the lungs. 
the lung. Therefore, this organ is in a location 
to fully receive the impact of mediators re- 
leased down stream. This observation was of 
great interest, since the pulmonary injury 
post hepatic ischemia/reperfusion mimicked 
the pattern of injury following direct intra- 
venous administration of recombinant TNF 
to rats. As previously reported [35] recombi- 
nant TNF induces punctate pulmonary hem- 
orrhage associated with vascular permeability 
changes and neutrophil adhesion. Interest- 
ingly, pretreatment of rats prior to ischemia/ 
reperfusion with neutralizing antibodies 
dramatically reduced the pulmonary injury 
pattern. The anti-TNF antibody therapy re- 
duced the lung permeability changes from a 
mean permeability index of 0.6 to 0.2 
(p < 0.05) using preimmune sera as compared 
to anti-TNF sera, respectively. In addition to 
salvaging the lung, the antibody treatment 
significantly decreased the pathology of the 
liver itself. This was identified as a mainte- 
nance of hepatocyte integrity and a reduction 
of neutrophilic infiltrates. 
Although the cellular source of TNF in the 
ischemia/reperfusion model has not been 
identified, it is likely that the Kupffer cells 
(fixed liver macrophages) are the source of 
this cytokine. Past studies have shown that 
cultured rat Kupffer cells can be stimulated 
to produce significant amounts of TNF [36]. 
Since the Kupffer cell population in the liver 
represents a significant macrophage popula- 
tion, the production of inflammatory media- 
tors by these cells could be formidable. The 
production of systemic TNF during ischemia/ 
reperfusion could account for much of the 
pathophysiology associated with this injuri- 
ous process. 
TNF associated with transplant rejection 
It is becoming clear that TNF is a proximal 
mediator that may influence a number of 
important pathologic events. The above stud- 
ies exemplify this observation, as TNF is 
generated rapidly during ischemia/reperfu- 
sion injury. Yet, the consequence of acutely 
generated TNF on disease states that become 
chronic is not clear. For example, transplant 
tissues are subjected to severe ischemic insults 
during the course of many hours. The effect 
of proximal TNF production on long term 
organ survival may be an important issue, as 
this cytokine may set in motion a cascade of 
events that are manifested at later time 
points. In an attempt to examine the role of 
TNF in such a setting, an allograft heart 
transplant model was established in HLA 
mismatched rats. A heart from a brown Nor- 
way rat was grafted into the carotid vascula- 
ture of a Lewis rat. In this model normal 
rejection occurs at approximately 7 days. At 
this time point, the donor heart exhibits the 
classic histology of a cell-mediated, delayed 
type hypersensitivity reaction. A one time 
injection of anti-TNF antibody to the rats, at 
time of heart transplant, prolonged the graft 
survival 2-3  fold. Instead of rejecting the 
graft at day 7, the graft lasted until approxi- 
mately day 16. The therapeutic efficacy of the 
antibody treatment was also observed when 
administration was delayed for 24-36 hours. 
Interestingly, a immunohistochemical analy- 
sis for antigenic TNF in the donor heart at 
day 6, in nontreated animals, revealed an 
intense staining pattern for TNF (Figure 1). 
Clearly demonstrating that TNF is present 
in the graft during the actual rejection. 
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Fig. L Immunohistochemical analysis of  rat heart 6 days post transplant. In both A and B a large inflammatory cell infiltrate can 
be seen. Frame A is stained with specific antibody to rodent TNF,  Frame B is stained using preimmune sera. The arrows point out 
cells positive for TNF.  
Additional studies will be needed to deter- 
mine if continued antibody infusion will 
prove to be more efficacious than a one-time 
bolus injection. These findings both support 
and expand previous reports that TNF is 
important in both delayed type hypersensitiv- 
ity reactions and allograft rejection [32, 37]. 
TNF assumes an additional, important 
role in aspects of transplant immunology. 
Patients who are actively rejecting allografts 
will often be treated with the antibody OKT 
3, which effectively eliminates the CD3 posi- 
tive cells from the circulation. Administration 
of this antibody causes significant patient dis- 
tress with the development of fever, chills, 
rigors, headaches, and gastrointestinal dis- 
tress. This same constellation of symptoms is 
often observed after giving exogeneous, re- 
combinant TNF to human patients [38]. Two 
recent reports have indicated that there are 
transient, marked elevations of circulating 
TNF following OKT 3 therapy [39, 40]. We 
have also documented the appearance of cir- 
culating TNF under these circumferences. 
Three patients who were rejecting their renal 
allografts received OKT 3 therapy; 2 of these 
developed detectable levels of TNF in the 
peripheral circulation shortly after the first 
injection. Interestingly, none of these patients 
developed symptoms after the second injec- 
tion, and no TNF was detectable in the pe- 
ripheral blood. These data provide further 
insight into the pathophysiology of endoge- 
neous TNF production. 
Conclusion 
It is becoming increasingly apparent that 
variations in the quantity and spectrum of 
cytokines that are produced locally and/or 
systemically are important to the overall 
pathophysiology of the immune reaction. 
This general concept has proven useful in 
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assessing the multiple changes induced during 
sepsis and shock-like states, but has not been 
thoroughly explored in other pathologic pro- 
cesses. In the above studies we have examined 
the role of TNF in two diverse states. In an 
animal model of hepatic ischemia/reperfu- 
sion, TNF appears to be generated very early 
during reperfusion and is instrumental in in- 
ducing injury in tissue distal to the liver. The 
lungs appear to be especially susceptible to 
pathologic alterations due to hepatic is- 
chemia/reperfusion and the ARDS-like syn- 
drome associated with some post-liver 
ischemic events may have a TNF component. 
Tumor necrosis factor also appears to be 
important in the alterations that occur during 
the rejection of transplanted organs. There is 
little doubt that ischemia/reperfusion is un- 
avoidable during the transplant process and 
this may lead to TNF induced alterations. It 
is of great therapeutic interest that neutraliz- 
ing antibody to TNF can ameliorate some of 
the adverse effects of these disorders. Finally, 
it is worthy to study endogeneous mecha- 
nisms that may account for the "normal" 
regulation of TNF. Natural mediators, such 
as PGE2, TGF-beta, and IL-4 are all logical 
candidates that may have potential clinical 
efficacy. Continued research directed at un- 
derstanding this fascinating polypeptide me- 
diator is needed to fully identify its role in 
health and disease. 
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